Article Text

Download PDFPDF
Delayed autoimmune haemolytic anaemia after artesunate therapy for severe malaria
  1. Mostafa Abohelwa1,
  2. Veena Agusala2,
  3. Mona Hassan3 and
  4. Amal Gharamti4
  1. 1Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  2. 2School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  3. 3Department of Internal Medicine, Hematology/Oncology Division, American University of Beirut, Beirut, Lebanon
  4. 4Department of Internal Medicine, Yale School of Medicine, Waterbury Hospital, Waterbury, Connecticut, USA
  1. Correspondence to Dr Mostafa Abohelwa; mostafa.abohelwa{at}


We report the case of a 51-year-old man with severe malaria, who developed delayed autoimmune haemolytic anaemia following artesunate therapy. Delayed autoimmune haemolytic anaemia following artesunate therapy has been previously described. Its diagnosis can be challenging in the setting of possible dengue coinfection. Clinicians should be vigilant of this potential side effect of artesunate therapy, especially in patients who later develop signs and symptoms of haemolytic anaemia.

  • malignant and benign haematology
  • infectious diseases

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors MA wrote the initial draft, AG, MH and VA helped in editing the manuscript, final revision and adding to the discussion section.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.